

Abstract

An agent for producing medication for the treatment of depression and/or dementia disorders improves the effectivity of treatment of this illness compared to classical therapy through a combination of a substance which increases the dopamine concentration in the synaptic gap of the nerve cells of the brain and a local anaesthetic of the anilide group.